BioMimetic Therapeutics (BMTI)
Your Dashboard
Displaying BMTI Charts
Personalize your Dashboard. You can add and remove charts, drag and drop them into the order you
like, and we'll save your settings for the next time you visit when you're logged in.
Log in here or Click here to register for your free account.
Select or add more charts
- Accounts Payable 0.7364M
- Accounts Receivable 0.5588M
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization 0.0227
- Beneish M-Score Pro
- Beta Pro
- Book Value 48.81M
- Book Value per Share 1.735
- Capital Expenditures 0.0093M
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing 0.0279M
- Cash Financing TTM 0.2073M
- Cash Investing 8.801M
- Cash Investing TTM 22.93M
- Cash Operations -6.883M
- Cash Operations TTM -27.66M
- Cash and Equivalents 20.45M
- Cash and ST Investments 54.51M
- Current Ratio 14.66
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio 0.0023
- Dividend
- Dividend Yield 0.00%
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share -0.22
- Earnings Per Share Growth
- Earnings Per Share TTM -1.13
- Earnings Yield -46.50%
- Effective Tax Rate TTM Pro
- Enterprise Value 48.02M
- Expenses 6.584M
- Expenses TTM 33.15M
- Free Cash Flow -6.892M
- Free Cash Flow TTM -28.88M
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin 96.68%
- Gross Profit TTM 1.736M
- Income from Cont. Ops Pro
- Interest Expense 0.00
- Interest Income 0.0219M
- Inventories 3.537M
- KZ Index Pro
- Liabilities 18.13M
- Long Term Debt 0.1105M
- Market Cap 68.36M
- Net Income -6.117M
- Net Income TTM -31.35M
- Net PP&E 4.949M
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price 2.43
- Price / Book Value 1.400
- Price / Sales Ratio 38.13
- Price / Tangible Book Value Pro
- Profit Margin -1312%
- R&D Expense 2.768M
- Receivables Turnover 2.720
- Retained Earnings -166.76M
- Retained Earnings Growth
- Return on Assets -37.90%
- Return on Equity -50.43%
- Return on Invested Capital Pro
- Revenue Growth 16.98%
- Revenue Per Share TTM 0.0637
- Revenues 0.4664M
- Revenues TTM 1.793M
- SG&A Expense 3.448M
- Shareholders Equity 48.81M
- Shares Outstanding 28.13M
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets 66.94M
- Total Return Price 2.43
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
What do these terms mean? Read all about them in the Glossary.
You may also be interested in these BMTI related companies
BMTI News
Listen to $BMTI Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3kfu
about 18 days ago by earningscast
about 18 days ago by earningscast
BioMimetic Therapeutics, Inc. Reports First Quarter 2012 Earnings Results
May 09, 4:00PM Business Wire
May 09, 4:00PM Business Wire
BioMimetic Therapeutics, Inc. to Report First Quarter 2012 Financial Results on May 9
May 07, 11:00AM Business Wire
May 07, 11:00AM Business Wire
BioMimetic (BMTI) Shares Rallying on Very Heavy Volume, Stock Now Up Nearly 7%
Apr 04, 1:53PM Street Insider
Apr 04, 1:53PM Street Insider
@ACInvestorBlog $BMTI - what developments do you see that might move this stock up or down? And forget about insider purchases.
about 54 days ago by gregthor
about 54 days ago by gregthor
Listen to $BMTI Q4 2011 earnings call - live at 04:30 PM, ondemand after - http://stks.co/2pPl
about 75 days ago by earningscast
about 75 days ago by earningscast
BioMimetic Therapeutics, Inc. (BMTI) Posts Wider than Expected Q4 Loss
Mar 13, 4:00PM Street Insider
Mar 13, 4:00PM Street Insider
BioMimetic Therapeutics, Inc. Reports Fourth Quarter and Year-End 2011 Earnings Results
Mar 13, 4:00PM Business Wire
Mar 13, 4:00PM Business Wire
BioMimetic Therapeutics, Inc. to Report 2011 Fourth Quarter and Year-End Financial Results on March 13
Mar 09, 2:27PM Business Wire
Mar 09, 2:27PM Business Wire
$BMTI http://stks.co/2kdZ Look For A Move Over The Range Break And Then 50 EMA At 2.24.
about 80 days ago by XiATH
about 80 days ago by XiATH
BioMimetic Therapeutics, Inc. to Introduce Augmatrix™ Biocomposite Bone Graft Product Line at AAOS
Feb 08, 9:25AM Business Wire
Feb 08, 9:25AM Business Wire
$BMTI too risky. Strong Buys $SINO,target $6 $ONTY $OCZ lots of room to run
about 110 days ago by contrarian1
about 110 days ago by contrarian1
Collins Stewart Reiterates a 'Buy' on BioMimetic Therapeutics (BMTI); Positive Pilot Study Offer Another Sizable Opportunity
Feb 07, 11:05AM Street Insider
Feb 07, 11:05AM Street Insider
BioMimetic Therapeutics, Inc. to Highlight Product Development Activities at ORS and AAOS Meetings
Feb 06, 4:00PM Business Wire
Feb 06, 4:00PM Business Wire
BioMimetic Therapeutics, Inc. to Present at the 30th Annual J.P. Morgan Healthcare Conference
Jan 10, 11:00AM Business Wire
Jan 10, 11:00AM Business Wire
Wedbush Downgrades BioMimetic Therapeutics (BMTI) to Neutral, Still See Approval of Augment Bone Graft
Jan 04, 12:18PM Street Insider
Jan 04, 12:18PM Street Insider
$BMTI BioMimetic Therapeutics downgraded to Neutral from Outperform at Wedbush
about 144 days ago by _TheBlackSwan_
about 144 days ago by _TheBlackSwan_
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BMTI | 2.43 | +0.02 | +0.83% | 68.36M |
| BMRN | 38.64 | +0.13 | +0.34% | 4.468B |
| BMJ | 0.93 | +0.00 | +0.00% | |
| BMI | 36.69 | -0.25 | -0.68% | 550.35M |
| BMC | 43.69 | +0.72 | +1.68% | 7.175B |
| BMA | 13.46 | -0.33 | -2.39% | 785.12M |
| BLX | 19.14 | -0.08 | -0.42% | 540.90M |
| BLV | 93.83 | +0.41 | +0.44% | |
| BLTI | 2.42 | +0.06 | +2.54% | 74.27M |
| BLT | 13.53 | -0.11 | -0.81% | 662.16M |
